Brief: Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting Officer - SEC Filing
10/04/2025 21:51
April 10 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O: BIOCRYST PHARMACEUTICALS - ON APRIL 7, JON P. STONEHOUSE APPOINTED INTERIM CFO & INTERIM PRINCIPAL ACCOUNTING OFFICER - SEC FILING Source text: [ID:n0001171843-25-002147] Further company coverage: BCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026